Anti-Human VEGF Recombinant Antibody Fab Fragment (TAB-012-F(E)) (CAT#: TAB-012-F(E))

• Immunogen
• Purified intact human VEGF

• Host Species
• Mouse

• Derivation
• Humanized (from mouse)

• Type
• Fab - G1 - kappa

• Specificity
• Tested positive against native human antigen

• Species Reactivity
• Human

• Applications
• IP, IF, FuncS, FC, Neut, ELISA, IHC

• MW
• 48350 g/mol

• Related Disease
• Diabetic retinopathy

• Purity
• >95.0% as determined by analysis by SDS-PAGE.

• Storage
• Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.

• Application Notes
• The VEGFA antibody has been reported in applications of Activ, Migration, SPR, Dot, H&E staining, IHC, RT-PCR, ELISA.
  Migration: An aliquot of resuspended cells (250 μl; ~50,000 cells/well) was placed in the upper well of the ECM plate, and MBM (750 μl) with or without ligand (130 pM human VEGF-A165, 7.1 nM human PLGF-2, or 3.5 nM mouse PLGF-2), was mixed with VEGF Trap, bevacizumab, or ranibizumab (inhibitor concentration range 0.013–13 nM) and placed in the lower well following a 1 h incubation of the mixture at room temperature. The ECM plate was incubated for 18–20 h in a 37°C/5% CO2 incubator to allow cells from the upper well to migrate through the FluoroBlok™ membrane towards the lower well. Following migration, cells attached to the underside of the FluoroBlok™ membrane were stained with 500 μL of a 2 μg/mL solution of the fluorescent dye Calcein AM for 1.5 h in a 37°C/5% CO2 incubator.
  IHC: Retinal cross-sections (n = 7–10 eyes/group) were prepared for immunohistochemistry. After drying and rehydration in PBS, sections were blocked in 10–20% appropriate serum with 1% BSA in 0.1% or 0.2% Triton X-100 in PBS. Three retinal sections per eye were used for each staining. RGCs, cholinergic amacrine cells, (active) microglia as well as macroglia, the synaptic ribbon terminals, photoreceptors as well as the VEGF-receptor 2 were investigated using specific antibodies. The primary antibodies were incubated at room temperature overnight. Incubation with corresponding secondary antibodies was performed for 60 min. As a nuclear stain DAPI was added. Negative controls were implemented by using secondary antibodies only.
  ELISA: A total of 96 well plates were coated with recombinant human VEGF165 at a concentration of 1.0 μg/mL overnight at 4°C (100 μL/well). After washing three times with PBS containing 0.05% Tween-20, the wells were blocked with 3% BSA/PBS overnight at 4°C (200 μL/well), washed five times with PBS containing 0.05% Tween-20, and stored dry at 4°C for later use.

• Alternative Names
• Ranibizumab;ranibizumab;347396-82-1;DB01270VEGFA;vascular endothelial growth factor A;vascular endothelial growth factor , VEGF;VEGF A;VPF;vascular permeability factor;VEGF;MVCD1;MGC70609;

• Gene ID
• 7422

• UniProt ID
• P15692

Select a product category from the dropdown menu below to view related products.